Spero Therapeutics, Inc. (SPRO) — 8-K Filings

8-K Filings (21)

• Spero Therapeutics Files 8-K — Dec 19, 2025 Risk: low
  On December 19, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specif
• Spero Therapeutics Files 8-K on Financials — Aug 12, 2025 Risk: low
  Spero Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Spero Therapeutics Reports Director/Officer Changes & Shareholder Votes — Jun 18, 2025 Risk: medium
  Spero Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting events that occurred on June 12, 2025. The filing indicates changes related to the departure o
• Spero Therapeutics Files 8-K Report — May 28, 2025 Risk: low
  On May 28, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
• Spero Therapeutics Files 8-K on Financials — May 13, 2025 Risk: low
  On May 13, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
• Spero Therapeutics Files 8-K: Officer/Director Changes & Financials — Apr 28, 2025 Risk: medium
  On April 22, 2025, Spero Therapeutics, Inc. filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and up
• Spero Therapeutics Files 8-K on Financials — Mar 27, 2025 Risk: low
  On March 27, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Spero Therapeutics to be Delisted from Nasdaq — Feb 28, 2025 Risk: high
  Spero Therapeutics, Inc. announced on February 25, 2025, that its common stock will be delisted from the Nasdaq Capital Market. The company received a notice fr
• Spero Therapeutics Files 8-K — Jan 10, 2025 Risk: low
  Spero Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting on events as of January 7, 2025. The filing includes information on results of operations,
• Spero Therapeutics Files 8-K on Financials — Nov 14, 2024 Risk: low
  Spero Therapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Spero Therapeutics Files 8-K — Oct 29, 2024 Risk: low
  Spero Therapeutics, Inc. filed an 8-K on October 29, 2024, reporting on its financial condition and other events. The filing indicates the company's principal e
• Merck Acquires Spero Therapeutics for $277M — Sep 10, 2024 Risk: medium
  Spero Therapeutics, Inc. announced on September 9, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $11.00 per shar
• Spero Therapeutics Files 8-K — Aug 5, 2024 Risk: low
  Spero Therapeutics, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations, financial condition, and providing Regulation FD disclosures. T
• Spero Therapeutics Announces Director Changes and Shareholder Votes — Jun 3, 2024 Risk: medium
  On May 29, 2024, Spero Therapeutics, Inc. announced the departure of Director David E. Melnick and the election of new Director Jonathan J. Lim. The company als
• Spero Therapeutics Files 8-K on Financials — May 15, 2024 Risk: low
  On May 15, 2024, Spero Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing indicates the company's pr
• Merck Acquires Spero Therapeutics for $1.1 Billion — Mar 29, 2024 Risk: medium
  Spero Therapeutics, Inc. announced on March 29, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $1.1 billion in ca
• Spero Therapeutics Files 8-K on Financials — Mar 13, 2024 Risk: low
  On March 13, 2024, Spero Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial state
• SPRO 8-K: Executive/Director Changes, Compensation Arrangements — Feb 9, 2024 Risk: medium
  Spero Therapeutics, Inc. filed an 8-K on February 9, 2024, reporting an event that occurred on February 5, 2024, related to changes in its executive team or dir
• Spero Therapeutics Files 8-K on Jan 8, Signals New Material Info — Jan 8, 2024
  Spero Therapeutics, Inc. filed an 8-K on January 8, 2024, to report a current event. This filing, under Regulation FD Disclosure and Financial Statements and Ex
• Spero Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — Jan 5, 2024
  Spero Therapeutics, Inc. filed an 8-K on January 5, 2024, to report on its current status, including its common stock trading on The Nasdaq Global Select Market
• Spero Therapeutics Files Routine 8-K on Jan 2, 2024 — Jan 2, 2024
  Spero Therapeutics, Inc. filed an 8-K on January 2, 2024, to report a routine event, likely an update on corporate governance or a minor operational change, as

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX